

NIPA1 siRNA (r): sc-270012

BACKGROUND

NIPA1 (non imprinted in Prader-Willi/Angelman syndrome 1), also known as SPG6 or FSP3, is a 329 amino acid multi-pass membrane protein that exists as multiple alternatively spliced isoforms and is expressed at high levels in neuronal tissue. NIPA1 is thought to play a role in nervous system development and, when defective, is involved in the pathogenesis of spastic paraplegia autosomal dominant type 6 (SPG6), a degenerative spinal cord disease characterized by the progressive weakening of the lower limbs. The gene encoding NIPA1 maps to human chromosome 15, which houses over 700 genes and comprises nearly 3% of the human genome. Angelman syndrome, Prader-Willi syndrome, Tay-Sachs disease and Marfan syndrome are all associated with defects in chromosome 15-localized genes.

REFERENCES

1. Fink, J.K., et al. 1995. Autosomal dominant familial spastic paraplegia: tight linkage to chromosome 15q. *Am. J. Hum. Genet.* 56: 188-192.
2. Fink, J.K., et al. 1995. Autosomal dominant, familial spastic paraplegia, type I: clinical and genetic analysis of a large North American family. *Neurology* 45: 325-331.
3. Chai, J.H., et al. 2003. Identification of four highly conserved genes between breakpoint hotspots BP1 and BP2 of the Prader-Willi/Angelman syndromes deletion region that have undergone evolutionary transposition mediated by flanking duplicons. *Am. J. Hum. Genet.* 73: 898-925.
4. Rainier, S., et al. 2003. NIPA1 gene mutations cause autosomal dominant hereditary spastic paraplegia (SPG6). *Am. J. Hum. Genet.* 73: 967-971.
5. Chen, S., et al. 2005. Distinct novel mutations affecting the same base in the NIPA1 gene cause autosomal dominant hereditary spastic paraplegia in two Chinese families. *Hum. Mutat.* 25: 135-141.
6. Reed, J.A., et al. 2005. A novel NIPA1 mutation associated with a pure form of autosomal dominant hereditary spastic paraplegia. *Neurogenetics* 6: 79-84.
7. Online Mendelian Inheritance in Man, OMIM™. 2006. Johns Hopkins University, Baltimore, MD. MIM Number: 608145. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>

CHROMOSOMAL LOCATION

Genetic locus: Nipa1 (rat) mapping to 1q22.

PRODUCT

NIPA1 siRNA (r) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see NIPA1 shRNA Plasmid (r): sc-270012-SH and NIPA1 shRNA (r) Lentiviral Particles: sc-270012-V as alternate gene silencing products.

For independent verification of NIPA1 (r) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-270012A, sc-270012B and sc-270012C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

NIPA1 siRNA (r) is recommended for the inhibition of NIPA1 expression in rat cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

NIPA1 (E-4): sc-398041 is recommended as a control antibody for monitoring of NIPA1 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG κ BP-HRP: sc-516102 or m-IgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-IgG κ BP-FITC: sc-516140 or m-IgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 or UltraCruz® Hard-set Mounting Medium: sc-359850.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor NIPA1 gene expression knockdown using RT-PCR Primer: NIPA1 (r)-PR: sc-270012-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.